CD274 and non-small cell lung carcinoma: The PACIFIC study is a randomized double-blind phase III trial that compared consolidation therapy with the anti-PDL1 Durvalumab versus placebo in unresectable LA-NSCLC patients who did not progress after platinum-based cCRT [96].